Title:
NKG2D EXPRESSING CAR-T CELLS
Document Type and Number:
WIPO Patent Application WO/2023/245042
Kind Code:
A3
Abstract:
Disclosed herein are immune effector cells that are expanded and enriched for NKG2D expression and genetically modified to express chimeric antigen receptor (CAR) polypeptides that can be used with adoptive cell transfer to target and kill CD33-expressing and/or CD123-expressing cancers. In some embodiments, the immune effector cells are gamma-delta (γδ) T cells, Natural Killer (NK) cells, or a combination thereof.
Inventors:
DAVILA MARCO (US)
Application Number:
PCT/US2023/068414
Publication Date:
February 15, 2024
Filing Date:
June 14, 2023
Export Citation:
Assignee:
H LEE MOFFITT CANCER CT & RES (US)
International Classes:
A61K35/17; A61K39/00; C07K14/725
Domestic Patent References:
| WO2019060174A1 | 2019-03-28 |
Foreign References:
| US20210024608A1 | 2021-01-28 |
Attorney, Agent or Firm:
GILES, Brian P. (US)
Download PDF: